Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19.3M
-
Number of holders
-
250
-
Total 13F shares, excl. options
-
22.5M
-
Shares change
-
-626K
-
Total reported value, excl. options
-
$2.34B
-
Value change
-
-$63.5M
-
Put/Call ratio
-
1.94
-
Number of buys
-
78
-
Number of sells
-
-154
-
Price
-
$104.29
Significant Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) as of Q4 2019
306 filings reported holding LGND - LIGAND PHARMACEUTICALS INC - Common Stock as of Q4 2019.
LIGAND PHARMACEUTICALS INC - Common Stock (LGND) has 250 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22.5M shares
.
Largest 10 shareholders include BlackRock Inc. (2.39M shares), JANUS HENDERSON GROUP PLC (1.82M shares), VANGUARD GROUP INC (1.57M shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (1.42M shares), STATE STREET CORP (1.25M shares), RENAISSANCE TECHNOLOGIES LLC (1.02M shares), CARDINAL CAPITAL MANAGEMENT LLC /CT (920K shares), MACQUARIE GROUP LTD (639K shares), Conestoga Capital Advisors, LLC (620K shares), and Thrivent Financial for Lutherans (528K shares).
This table shows the top 250 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.